Vu Quan Anh, the Chief Financial Officer of Monopar Therapeutics, has reported several transactions involving the company's common stock and restricted stock units. This filing is significant as it underscores his continued investment in the company, which may bolster investor confidence and signal stability in leadership.
Monopar Therapeutics, identified by the Central Index Key 0001645469, operates within the pharmaceutical preparations sector. The company is based in Wilmette, Illinois, and is focused on developing innovative therapies. Vu Quan Anh's recent filing, dated October 2, 2026, follows a series of similar disclosures, indicating an active engagement in the company's financial activities.
The recent filing reveals that on September 30, 2026, Vu Quan Anh acquired 614 shares of common stock through the vesting of restricted stock units. Additionally, he reported the acquisition of another 180 shares, which were withheld to cover tax obligations related to the vesting of the same restricted stock units. Following these transactions, he now holds a total of 7,984 shares of common stock in Monopar Therapeutics.
These transactions may impact various stakeholders, including investors and analysts who monitor the company's financial health and leadership decisions. The filing indicates a direct ownership of shares, which reflects a commitment to the company's future and could enhance confidence among shareholders.
Details were not available in the SEC filing regarding future plans or additional transactions. The filing does not say what happens next.